153 related articles for article (PubMed ID: 38626148)
21. The 2020 revision of the guidelines for the management of myeloproliferative neoplasms.
Kim SY; Bae SH; Bang SM; Eom KS; Hong J; Jang S; Jung CW; Kim HJ; Kim HY; Kim MK; Kim SJ; Mun YC; Nam SH; Park J; Won JH; Choi CW
Korean J Intern Med; 2021 Jan; 36(1):45-62. PubMed ID: 33147902
[TBL] [Abstract][Full Text] [Related]
22. The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?
Hasselbalch HC
Leuk Res; 2014 Oct; 38(10):1230-6. PubMed ID: 25149709
[TBL] [Abstract][Full Text] [Related]
23. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
[TBL] [Abstract][Full Text] [Related]
24. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
25. Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms.
Yoon SY; Kim SY
Korean J Intern Med; 2023 Nov; 38(6):810-817. PubMed ID: 37939664
[TBL] [Abstract][Full Text] [Related]
26. Mutations in the miR-142 gene are not common in myeloproliferative neoplasms.
Galka-Marciniak P; Kanduła Z; Tire A; Wegorek W; Gwozdz-Bak K; Handschuh L; Giefing M; Lewandowski K; Kozlowski P
Sci Rep; 2022 Jun; 12(1):10924. PubMed ID: 35764886
[TBL] [Abstract][Full Text] [Related]
27. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
28. Analysis of clinical characteristics of bone marrow proliferative tumor progression to acute myeloid leukemia.
Li Y; Zhang XY; Han J; Wang L
Cancer Biomark; 2018; 23(4):469-472. PubMed ID: 30452397
[TBL] [Abstract][Full Text] [Related]
29. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
30. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
31. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
32. Future therapies for the myeloproliferative neoplasms.
Scherber R; Mesa RA
Curr Hematol Malig Rep; 2011 Mar; 6(1):22-7. PubMed ID: 21080242
[TBL] [Abstract][Full Text] [Related]
33. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
34. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
35.
Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H
Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
[TBL] [Abstract][Full Text] [Related]
37. Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D; Mascarenhas J
Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
[TBL] [Abstract][Full Text] [Related]
38. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
39. Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.
Mora B; Passamonti F
Curr Hematol Malig Rep; 2022 Oct; 17(5):127-139. PubMed ID: 36048275
[TBL] [Abstract][Full Text] [Related]
40. Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey.
Ishida H; Miyajima Y; Hyakuna N; Hamada S; Sarashina T; Matsumura R; Umeda K; Mitsui T; Fujita N; Tomizawa D; Urayama KY; Ishida Y; Taga T; Takagi M; Adachi S; Manabe A; Imamura T; Koh K; Shimada A;
EJHaem; 2020 Jul; 1(1):86-93. PubMed ID: 35847744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
